UNC1999 aggravated genotoxic effects induced by treatments of olaparib, an FDA approved PARP inhibitor in cells deficient in DDR pathways, enhancing its synthetic lethal effects in BRCA-deficient cell lines and AML patient cells (Caruso et al., 2018). This evidence concerns the gene PARP1 and acute myeloid leukemia.